Ludwig Enterprises Launches Growth Plan

Rhea-AI Summary

Ludwig Enterprises has announced a strategic partnership with The Fannon Group to enhance sales and marketing for its key products, including the mRNA Inflammatory Index. This patent-pending technology aims to evaluate inflammation biomarkers, potentially helping healthcare professionals in early illness detection and management. CEO Luke Fannon brings over 30 years of experience, which aims to boost the company's market presence. Ludwig's innovative approach is positioned to significantly impact the billion-dollar healthcare sector and improve patient outcomes, potentially saving costs in the industry.

Positive

• Strategic partnership with The Fannon Group to boost sales and marketing.
• mRNA Inflammatory Index technology may aid in early disease detection and management.
• Luke Fannon's extensive experience expected to enhance product launch success.

Negative

• None.

SPARKS, NV / ACCESSWIRE / February 14, 2023 / Ludwig Enterprises, developers of the Inflammatory Index (Patent Pending) and owners of the mRNA For Life nutritional supplement is pleased to announce that it has entered into an agreement with The Fannon Group, to provide healthcare sales and marketing leadership as they begin marketing their flagship products.

"The Fannon Group and its CEO Luke is a great addition to the team," said Anne Blackstone President of Ludwig Enterprises. "Luke and his team's expertise in healthcare sales and marketing will help ensure a successful launch of our products."

Founded in 2005 The Fannon Group has helped hundreds of healthcare organizations grow revenue and profitability. Luke Fannon, CEO of the Fannon Group, has over 30 years of experience in healthcare sales and marketing including over 10 years of c-suite leadership roles with a number of healthcare companies.

About Ludwig Enterprises, Inc.

Ludwig Enterprises, Inc. has a patent pending on the mRNA Inflammatory Index that measures 48 different biomarkers of inflammation. Combined with AI and deep machine learning this technology may enable healthcare professionals to identify sources of chronic inflammation and potentially prevent chronic illnesses such as diabetes, COPD, heart disease and cancer.

Advancements in medical technology have awarded us with cutting-edge genomic tools, unheard of even a generation ago. These genomic tools have the potential to not only detect diseases early but also to customize treatments that may improve patient outcomes and, in some cases, even extend life. Ludwig is at the forefront of this new era of medicine with their proprietary mRNA genomic technology that has the potential to detect genetic biomarkers for inflammatory-driven diseases, including, but not limited to heart disease, diabetes, preeclampsia and cancer. This early detection may allow doctors to take steps to diagnose and manage illness before it progresses and causes serious health problems. Ludwig's innovative testing approach is not only practical but also has the potential to save the healthcare industry millions of dollars in cost. With a virtually untapped market and a billion-dollar healthcare industry, Ludwig and its subsidiary Precision Genomics is poised to significantly impact how we think about disease and live longer healthier lives. For more info please go to: http://www.ludwigent.com.

SAFE HARBOR

Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Precision Genomics & Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:

Ludwig Enterprises, Inc.
Anne Blackstone,
786-235-9026
www.ludwigent.com

SOURCE: Ludwig Enterprises, Inc.

View source version on accesswire.com:
https://www.accesswire.com/739288/Ludwig-Enterprises-Launches-Growth-Plan

FAQ

What is the strategic partnership announced by Ludwig Enterprises on February 14, 2023?

Ludwig Enterprises partnered with The Fannon Group to enhance sales and marketing for its mRNA Inflammatory Index and other products.

Who is Luke Fannon in relation to Ludwig Enterprises?

Luke Fannon is the CEO of The Fannon Group, which is assisting Ludwig Enterprises with healthcare sales and marketing.

What is the mRNA Inflammatory Index developed by Ludwig Enterprises?

It is a patent-pending technology that measures various biomarkers of inflammation and aims to assist in early disease detection.

How could Ludwig Enterprises' products impact the healthcare industry?

The products may improve early detection and management of chronic diseases, potentially saving costs in healthcare.

What does the forward-looking statement in Ludwig Enterprises' press release warn about?

It cautions that future performance may be affected by risks and uncertainties, which could lead to actual results differing from projections.